Compare Marathon Petroleum Corp (MPC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Marathon Petroleum Corp trades at $456.1 (market cap $130.12B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Marathon Petroleum Corp is far larger — about 12.9× State Street SPDR S&P Biotech ETF's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MPC | XBI | |
|---|---|---|
Market Cap | $130.12B | $10.11B |
Volume | 2,749,647 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $463.34 | $169.55 |
52-Week Low | $162.63 | $104.99 |
Typical Hold Time | 54 Days | 38 Days |
Enterprise Value | $156.64B | — |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $455.03, up 2.89% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 16.07, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds.
Outlook remains positive with 76% analyst buy ratings and $420.30 consensus target. Key opportunities include elevated refining margins and projected 2026 revenue growth to $153.6B. Risks include regulatory uncertainty around diesel exports and declining operating cash flow from 2022 peaks.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
